Dong-A acquires South Korean naftopidil rights
This article was originally published in Scrip
Japan's Asahi Kasei has licensed its benign prostatic hyperplasia therapy, naftopidil, to Dong-A Pharmaceutical for South Korea. The company has gained exclusive rights in its home market to develop and commercialise the alpha-1 antagonist, which was launched as Flivas in Japan in 1999. The molecule acts to relax prostate and urethral smooth muscle, and is also in Japanese clinical development for neurogenic bladder. Dong-A already has a presence in the urology sector through Zydena (udenafil), its PDE5-inhibitor for erectile dysfunction.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.